Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 103 - 114 |
| Number of pages | 12 |
| Journal | Brain, Behavior, and Immunity |
| Volume | 30 |
| DOIs | |
| Publication status | Published - 2013 |
Cite this
}
Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity. / Payne, Natalie Lisa; Sun, Guizhi; McDonald, Courtney; Moussa, Leon; Emerson-Webber, Ashley Colin; Loisel-Meyer, Severine; Medin, Jeff; Siatskas, Christopher; Bernard, Claude Charles Andre.
In: Brain, Behavior, and Immunity, Vol. 30, 2013, p. 103 - 114.Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Human adipose-derived mesenchymal stem cells engineered to secrete IL-10 inhibit APC function and limit CNS autoimmunity
AU - Payne, Natalie Lisa
AU - Sun, Guizhi
AU - McDonald, Courtney
AU - Moussa, Leon
AU - Emerson-Webber, Ashley Colin
AU - Loisel-Meyer, Severine
AU - Medin, Jeff
AU - Siatskas, Christopher
AU - Bernard, Claude Charles Andre
PY - 2013
Y1 - 2013
N2 - Interleukin (IL)-10 is an important immunoregulatory cytokine shown to impact inflammatory processes as manifested in patients with multiple sclerosis (MS) and in its animal model, experimental autoimmune encephalomyelitis (EAE). Several lines of evidence indicate that the effectiveness of IL-10-based therapies may be dependent on the timing and mode of delivery. In the present study we engineered the expression of IL-10 in human adipose-derived mesenchymal stem cells (Adi-IL-10-MSCs) and transplanted these cells early in the disease course to mice with EAE. Adi-IL-10-MSCs transplanted via the intraperitoneal route prevented or delayed the development of EAE. This protective effect was associated with several anti-inflammatory response mechanisms, including a reduction in peripheral T-cell proliferative responses, a decrease in pro-inflammatory cytokine secretion as well as a preferential inhibition of Th17-mediated neuroinflammation. In vitro analyses revealed that Adi-IL-10-MSCs inhibited the phenotypic maturation, cytokine production and antigen presenting capacity of bone marrow-derived myeloid dendritic cells, suggesting that the mechanism of action may involve an indirect effect on pathogenic T-cells via the modulation of antigen presenting cell function. Collectively, these results suggest that early intervention with gene modified Adi-MSCs may be beneficial for the treatment of autoimmune diseases such as MS.
AB - Interleukin (IL)-10 is an important immunoregulatory cytokine shown to impact inflammatory processes as manifested in patients with multiple sclerosis (MS) and in its animal model, experimental autoimmune encephalomyelitis (EAE). Several lines of evidence indicate that the effectiveness of IL-10-based therapies may be dependent on the timing and mode of delivery. In the present study we engineered the expression of IL-10 in human adipose-derived mesenchymal stem cells (Adi-IL-10-MSCs) and transplanted these cells early in the disease course to mice with EAE. Adi-IL-10-MSCs transplanted via the intraperitoneal route prevented or delayed the development of EAE. This protective effect was associated with several anti-inflammatory response mechanisms, including a reduction in peripheral T-cell proliferative responses, a decrease in pro-inflammatory cytokine secretion as well as a preferential inhibition of Th17-mediated neuroinflammation. In vitro analyses revealed that Adi-IL-10-MSCs inhibited the phenotypic maturation, cytokine production and antigen presenting capacity of bone marrow-derived myeloid dendritic cells, suggesting that the mechanism of action may involve an indirect effect on pathogenic T-cells via the modulation of antigen presenting cell function. Collectively, these results suggest that early intervention with gene modified Adi-MSCs may be beneficial for the treatment of autoimmune diseases such as MS.
UR - http://www.sciencedirect.com/science/article/pii/S0889159113000822
U2 - 10.1016/j.bbi.2013.01.079
DO - 10.1016/j.bbi.2013.01.079
M3 - Article
VL - 30
SP - 103
EP - 114
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
SN - 0889-1591
ER -